Hyperuricemia induces lipid disturbances mediated by LPCAT3 upregulation in the liver.

Potential underlying molecular mechanisms for uric acid‐induced lipid metabolic disturbances had not been elucidated clearly. This study investigated the effects and underlying mechanisms of uric acid on the development of lipid metabolic disorders. We collected blood samples from 100 healthy people and 100 patients with hyperuricemia for whom serum lipid analysis was performed. Meanwhile, a mouse model of hyperuricemia was generated, and lipidomics was performed on liver tissues, comparing control and hyperuricemia groups, to analyze lipid profiles and key metabolic enzymes. Uric acid directly induced serum lipid metabolic disorders in both humans and mice based on triglycerides, total cholesterol, and low‐density lipoprotein cholesterol. Through lipidomic analysis, 46 lipids were differentially expressed in hyperuricemic mouse livers, and the phosphatidylcholine composition was altered, which was mediated by LPCAT3 upregulation. High‐uric acid levels‐induced p‐STAT3 inhibition and SREBP‐1c activation in vivo and in vitro. Moreover, LPCAT3‐knockdown significantly attenuated uric acid‐induced p‐STAT3 inhibition, SREBP‐1c activation, and lipid metabolic disorders in L02 cells. In conclusion, uric acid induces lipid metabolic disturbances through LPCAT3‐mediated p‐STAT3 inhibition and SREBP‐1c activation. LPCAT3 could be a key regulatory factor linking hyperuricemia and lipid metabolic disorders. These results might provide novel insights into the clinical treatment of hyperuricemia. [ABSTRACT FROM AUTHOR]